首页> 外文OA文献 >Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease
【2h】

Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mortality in end-stage renal disease

机译:巨噬细胞抑制性细胞因子1(MIC-1 / GDF15)和终末期肾脏疾病的死亡率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background. Elevated macrophage inhibitory cytokine-1 (MIC-1/GDF15) levels in serum mediate anorexia and weight loss in some cancer patients and similarly elevated levels occur in chronic kidney disease (CKD). Serum MIC-1/GDF15 is also elevated in chronic inflammatory diseases and predicts atherosclerotic events independently of traditional risk factors. The relationship between chronic inflammation, decreasing body mass index (BMI) and increased mortality in CKD is not well understood and is being actively investigated. MIC-1/GDF15 may link these features of CKD.Methods. Cohorts of incident dialysis patients from Sweden (n = 98) and prevalent hemodialysis patients from the USA (n = 381) had serum MIC-1/GDF15, C-reactive protein (CRP) levels and BMI measured at study entry. Additional surrogate markers of nutritional adequacy, body composition and inflammation were assessed in Swedish patients. Patients were followed for all-cause mortality.Results. In the Swedish cohort, serum MIC-1/GDF15 was associated with decreasing BMI, measures of nutrition and markers of oxidative stress and inflammation. Additionally, high serum MIC-1/GDF15 levels identified patients with evidence of protein-energy wasting who died in the first 3 years of dialysis. The ability of serum MIC-1/GDF15 to predict mortality in the first 3 years of dialysis was confirmed in the USA cohort. In both cohorts, serum MIC-1/GDF15 level was an independent marker of mortality when adjusted for age, CRP, BMI, history of diabetes mellitus and/or cardiovascular disease and glomerular filtration rate or length of time on dialysis at study entry.Conclusions. MIC-1/GDF15 is a novel independent serum marker of mortality in CKD capable of significantly improving the mortality prediction of other established markers. MIC-1/GDF15 may mediate protein-energy wasting in CKD and represent a novel therapeutic target for this fatal complication.
机译:背景。在某些癌症患者中,血清中巨噬细胞抑制性细胞因子1(MIC-1 / GDF15)的水平升高介导了厌食和体重减轻,而慢性肾脏病(CKD)的水平也出现了类似的升高。血清MIC-1 / GDF15在慢性炎症性疾病中也升高,并独立于传统危险因素预测动脉粥样硬化事件。慢性炎症,体重指数(BMI)下降和CKD死亡率增加之间的关系尚未得到很好的了解,并且正在积极研究中。 MIC-1 / GDF15可以链接CKD.Methods的这些功能。瑞典入组透析患者(n = 98)和美国流行血液透析患者(n = 381)在研究开始时测定了血清MIC-1 / GDF15,C反应蛋白(CRP)水平和BMI。在瑞典患者中评估了营养充足,身体成分和炎症的其他替代指标。对患者进行全因死亡率随访。在瑞典队列中,血清MIC-1 / GDF15与BMI下降,营养指标以及氧化应激和炎症标志物有关。此外,高血清MIC-1 / GDF15水平确定了在透析的前3年中死亡的有蛋白质能量消耗证据的患者。在美国队列中证实了血清MIC-1 / GDF15预测透析的前3年死亡率的能力。在这两个队列中,在对年龄,CRP,BMI,糖尿病史和/或心血管疾病史以及肾小球滤过率或进行透析的时间进行调整后,血清MIC-1 / GDF15水平是死亡率的独立指标。 。 MIC-1 / GDF15是CKD中死亡率的新型独立血清标志物,能够显着改善其他已建立标志物的死亡率预测。 MIC-1 / GDF15可能介导CKD中蛋白质能量的浪费,并代表了这种致命并发症的新型治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号